Synonyms: AMG 509 | AMG-509 | AMG509
Compound class:
Antibody
Comment: Xaluritamig (AMG 509) is a humanised bispecific monoclonal antibody that targets six transmembrane epithelial antigen of the prostate 1 (STEAP1; on prostate tumour cells) and CD3e (on T cells) [2]. It is a bispecific T cell engager (BiTE) class monoclonal, that was designed for therapeutic use against prostate cancer. Engaging these two surface molecules facilitates immune mediated killing of STEAP1-expressing cancer cells. Cryo-electron microscopy reveals that the anti-STEAP1 Fab domain of xaluritamig binds to a STEAP1 homotrimer.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
References |
1. Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB et al.. (2024)
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov, 14 (1): 76-89. [PMID:37861461] |
2. Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, Li F, Zhang H, Case R, Murawsky CM et al.. (2024)
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discov, 14 (1): 90-103. [PMID:37861452] |